Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
28.00
-0.93 (-3.21%)
At close: Jan 8, 2026, 4:00 PM EST
27.98
-0.02 (-0.08%)
After-hours: Jan 8, 2026, 7:48 PM EST
Beam Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Beam Therapeutics stock have a consensus rating of "Buy" and an average price target of $46.42, which forecasts a 65.79% increase in the stock price over the next year. The lowest target is $21 and the highest is $80.
Price Target: $46.42 (+65.79%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Beam Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 4 | 3 | 4 | 5 | 5 | 5 |
| Hold | 2 | 2 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 11 | 12 | 12 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Initiates $28 | Hold | Initiates | $28 | n/a | Jan 7, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $35 | Buy | Initiates | $35 | +25.00% | Nov 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +185.71% | Oct 10, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $48 → $46 | Buy | Maintains | $48 → $46 | +64.29% | Oct 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +185.71% | Sep 15, 2025 |
Financial Forecast
Revenue This Year
37.98M
from 63.52M
Decreased by -40.21%
Revenue Next Year
48.05M
from 37.98M
Increased by 26.52%
EPS This Year
-4.58
from -4.58
EPS Next Year
-4.73
from -4.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 53.1M | 115.5M | ||||
| Avg | 38.0M | 48.0M | ||||
| Low | 15.7M | 29.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -16.4% | 204.1% | ||||
| Avg | -40.2% | 26.5% | ||||
| Low | -75.3% | -22.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -4.43 | -3.71 | ||||
| Avg | -4.58 | -4.73 | ||||
| Low | -4.81 | -5.96 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.